A promising new treatment for infants with Noonan syndrome
(University of Montreal) Infants less than six months old with Noonan Syndrome, hypertrophic cardiomyopathy and congestive heart failure normally have a poor prognosis, with a one-year survival rate of 34%. In the new study, doctors used Trametinib to try to treat NS in two patients.They observed dramatic improvement of clinical and cardiac status in the patients only three months after treatment. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 30, 2019 Category: International Medicine & Public Health Source Type: news

Apr 19 2019 This Week in Cardiology Apr 19 2019 This Week in Cardiology
Anticoagulation for embolic stroke of unknown origin, added-sugar labels, AF-patient knowledge, LDL-C and hemorrhagic stroke, and genetic signals in cancer-care cardiomyopathy are discussed this week.theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - April 19, 2019 Category: Cardiology Tags: Cardiology Commentary Source Type: news

Genetic Crosstalk in Cancer Therapy-Induced Cardiomyopathy Genetic Crosstalk in Cancer Therapy-Induced Cardiomyopathy
A genetic study links cancer-therapy-induced and dilated cardiomyopathies and signals how identification of genetic risk factors may help change management of those at risk.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 18, 2019 Category: Consumer Health News Tags: Cardiology News Source Type: news

Genetic Crosstalk in Cancer-Therapy-Induced Cardiomyopathy Genetic Crosstalk in Cancer-Therapy-Induced Cardiomyopathy
A genetic study links cancer-therapy-induced and dilated cardiomyopathies and signals how identification of genetic risk factors may help change management of those at risk.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - April 18, 2019 Category: Cardiology Tags: Cardiology News Source Type: news

Chagas Cardiomyopathy: The Disease You Might Not Think Of Chagas Cardiomyopathy: The Disease You Might Not Think Of
A growing public health threat demands more awareness of Chagas disease and its manifestations.Medscape Infectious Diseases (Source: Medscape Infectious Diseases Headlines)
Source: Medscape Infectious Diseases Headlines - April 16, 2019 Category: Infectious Diseases Tags: Infectious Diseases Case Challenge Source Type: news

A new role for genetics in cancer therapy-induced cardiomyopathy
(Brigham and Women's Hospital) A team of investigators from Brigham and Women's Hospital and Harvard Medical School finds that genetics may be at play and elucidates rare genetic variants which may influence risk for developing cancer therapy-induced cardiomyopathy. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 10, 2019 Category: International Medicine & Public Health Source Type: news

Computer Model Predicts Risk for Ventricular Arrythmia in ARVC
WEDNESDAY, April 3, 2019 -- A new model can predict the risk for incident ventricular arrhythmias (VAs) in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVC), according to a study published online March 27 in the European... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 3, 2019 Category: Pharmaceuticals Source Type: news

Atrial Arrhythmias in Takotsubo Syndrome Atrial Arrhythmias in Takotsubo Syndrome
Inflammation may be a predictor for new onset atrial arrhythmias in Takotsubo cardiomyopathy.Europace (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 22, 2019 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

ACC 2019: Medtronic, Edwards low-risk TAVR trial data could pave way to new indications
Results from trials of both Medtronic‘s (NYSE:MDT) and Edwards Lifesciences‘ (NYSE:EW) transcatheter aortic valve replacement systems exploring their use in low-risk patients indicated that the devices were as safe as open surgery, paving the way for possible new indications for TAVR technology. Data from the trials were presented over the weekend at the American College of Cardiology 68th Annual Scientific Session 2019 in New Orleans and simultaneously published in the New England Journal of Medicine. Currently, TAVR devices are only approved by the FDA for treating severe aortic valve stenosis in patients at inte...
Source: Mass Device - March 18, 2019 Category: Medical Devices Authors: Fink Densford Tags: Cardiac Implants Cardiovascular Clinical Trials Featured Replacement Heart Valves Edwards Lifesciences Medtronic Source Type: news

Novartis joins the Global Chagas Disease Coalition and also announces first multinational, prospective, randomized study in people with chronic Chagas cardiomyopathy
At the Annual Meeting of the Global Chagas Disease Coalition in Barcelona, Spain, Novartis announced that it is joining the Coalition as a member contributor. In addition, the company announced its commitment to launch a multinational, prospective, randomized study with heart failure drug, Entresto® (sacubitril / valsartan), in people with chronic Chagas cardiomyopathy, one form of heart failure with reduced ejection fraction. (Source: World Pharma News)
Source: World Pharma News - March 15, 2019 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news

Long - Term Cardiomyopathy Risk Varies by Chemo Agent
Decreased risk seen for daunorubicin versus doxorubicin among survivors of childhood cancer (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - March 1, 2019 Category: Cancer & Oncology Tags: Cardiology, Oncology, Pediatrics, Pharmacy, Journal, Source Type: news

Long-Term Cardiomyopathy Risk Varies by Chemo Agent
FRIDAY, March 1, 2019 -- Long-term cardiomyopathy risk varies by chemotherapy agent for childhood cancer survivors, with a decreased risk for daunorubicin versus doxorubicin, according to a study recently published in JAMA Oncology. Elizabeth A.M.... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 1, 2019 Category: Pharmaceuticals Source Type: news

What Is the Most Common Type of Cardiomyopathy?
Discussion Barth syndrome is characterized by a dilated cardiomyopathy, proximal skeletal muscle weakness, neutropenia and short stature that usually presents at birth or soon after. It is a rare X-linked recessive disease process caused by mutations in the TAZ gene. The TAZ gene codes for tafazzin which alters cardiolipin in mitochondria. Characteristic facies can be seen especially in infancy including a tall and broad forehead, prominent chin and full cheeks, larger ears, and deep-set eyes. Most patients present at birth or soon afterwards but some may not until later in life. Life expectancy is reduced with many childr...
Source: PediatricEducation.org - February 25, 2019 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

Scientists unravel genetic basis of hypertrophic cardiomyopathy in Finns
(University of Eastern Finland) One third of hypertrophic cardiomyopathy cases in Finland are caused by one of the four major mutations, a new study from the University of Eastern Finland and Kuopio University Hospital shows. Overall, 40 percent of patients carried a specific or a likely mutation causing the disease, and 20 percent were carriers of a rare gene mutation whose role in the disease remains unknown. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 22, 2019 Category: International Medicine & Public Health Source Type: news

Yale New Haven becomes first in CT to perform pediatric heart transplants
Families from Connecticut and Rhode Island will now have close access to pediatric care for congenital heart defects, cardiomyopathy, and other conditions. (Source: Yale Science and Health News)
Source: Yale Science and Health News - February 19, 2019 Category: Universities & Medical Training Source Type: news